CRISPR/Cas9 Technology–Based Xenograft Tumors as Candidate Reference Materials for Multiple EML4-ALK Rearrangements Testing
The DOI matches its Crossref record.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“this technique has been applied in preparing QC materials by introducing a targeted mutation into wild‐type cell lines in several studies.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 32
- Soda, 2007, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer, Nature, 448, 561, 10.1038/nature05945 · DOI · Paper page
- Roskoski, 2017, Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers, Pharmacol Res, 117, 343, 10.1016/j.phrs.2017.01.007 · DOI
- Arbour, 2017, Diagnosis and treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer, Hematol Oncol Clin North Am, 31, 101, 10.1016/j.hoc.2016.08.012 · DOI
- Liu, 2017, Recent development in the discovery of anaplastic lymphoma kinase (ALK) inhibitors for non-small cell lung cancer, Curr Med Chem, 24, 590, 10.2174/0929867323666161029223823 · doi:10.2174/0929867323666161029223823
- Cha, 2016, Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants, J Transl Med, 14, 296, 10.1186/s12967-016-1061-z · DOI
- Shaw, 2013, Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N Engl J Med, 368, 2385, 10.1056/NEJMoa1214886 · DOI · Paper page
- Solomon, 2016, Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014, J Clin Oncol, 34, 2858, 10.1200/JCO.2015.63.5888 · DOI · Paper page
- Hargrave, 2014, Previously unknown side effect of crizotinib emerges, Pharmacogenomics, 15, 260
- Teixido, 2014, Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements, Transl Lung Cancer Res, 3, 70
- Cruz-Rico, 2015, Diagnosis of EML4-ALK translocation with FISH, immunohistochemistry, and real-time polymerase chain reaction in patients with non-small cell lung cancer, Am J Clin Oncol
- Liu, 2016, Value of immunohistochemical methods in detecting EML4-ALK fusion mutations: a meta-analysis, Zhongguo Fei Ai Za Zhi, 19, 38
- von Laffert, 2017, Lung Cancer, 103, 1, 10.1016/j.lungcan.2016.11.008 · doi:10.1016/j.lungcan.2016.11.008
- Rekhtman, 2015, J Oncol Pract, 11, 135, 10.1200/JOP.2014.002303 · DOI
- Sabour, 2016, Reliability assurance of EML4-ALK rearrangement detection in non-small cell lung cancer: a methodological and statistical issue, J Clin Oncol, 11, e92
- Zhang, 2016, Comprehensive profiling and quantitation of oncogenic mutations in non small-cell lung carcinoma using single molecule amplification and re-sequencing technology, Oncotarget, 7, 50477, 10.18632/oncotarget.10464 · DOI
- Cui, 2017, Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer, Oncotarget, 8, 2771, 10.18632/oncotarget.13741 · DOI
- V Laffert, 2013, Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing, Lung Cancer, 81, 200, 10.1016/j.lungcan.2013.04.015 · DOI
- Lantuejoul, 2015, French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas, Eur Respir J, 46, 207, 10.1183/09031936.00119914 · DOI
- Xiao, 2009, Cell lines as candidate reference materials for quality control of ERBB2 amplification and expression assays in breast cancer, Clin Chem, 55, 1307, 10.1373/clinchem.2008.120576 · doi:10.1373/clinchem.2008.120576
- Li, 2016, Reliability assurance of detection of EML4-ALK rearrangement in non-small cell lung cancer: the results of proficiency testing in China, J Thorac Oncol, 11, 924, 10.1016/j.jtho.2016.03.004 · doi:10.1016/j.jtho.2016.03.004
- Sherry, 2001, dbSNP: the NCBI database of genetic variation, Nucleic Acids Res, 29, 308, 10.1093/nar/29.1.308 · DOI · Paper page
- Abecasis, 2012, An integrated map of genetic variation from 1,092 human genomes, Nature, 491, 56, 10.1038/nature11632 · DOI · Paper page
- Cong, 2013, Multiplex genome engineering using CRISPR/Cas systems, Science, 339, 819, 10.1126/science.1231143 · DOI · Paper page
- Wang, 2014, Genetic screens in human cells using the CRISPR-Cas9 system, Science, 343, 80, 10.1126/science.1246981 · DOI · Paper page
- Peng, 2016, Potential pitfalls of CRISPR/Cas9-mediated genome editing, FEBS J, 283, 1218, 10.1111/febs.13586 · DOI · Paper page
- Thunnissen, 2012, EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations, Virchows Arch, 461, 245, 10.1007/s00428-012-1281-4 · DOI · Paper page
- Kim, 2011, Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression, J Thorac Oncol, 6, 1359, 10.1097/JTO.0b013e31821cfc73 · DOI · Paper page
- Lam, 2015, Oncogenic mutation profiling in new lung cancer and mesothelioma cell lines, Onco Targets Ther, 8, 195, 10.2147/OTT.S71242 · DOI
- Akamatsu, 2014, Multiplexed molecular profiling of lung cancer using pleural effusion, J Thorac Oncol, 9, 1048, 10.1097/JTO.0000000000000203 · DOI
- Jang, 2016, Custom gene capture and next-generation sequencing to resolve discordant ALK status by FISH and IHC in lung adenocarcinoma, J Thorac Oncol, 11, 1891, 10.1016/j.jtho.2016.06.001 · DOI
- Mattsson, 2016, Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer, BMC Cancer, 16, 603, 10.1186/s12885-016-2646-x · DOI
- Zhang, 2017, Synthetic circulating cell-free DNA as quality control materials for somatic mutation detection in liquid biopsy for cancer, Clin Chem, 10.1373/clinchem.2017.272559 · DOI
Cited by
Zhou, L., Li, R., Zhang, R., Peng, R., Chen, K., Gao, P., Zhang, J., Zhang, R., & Li, J. (2020) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23256 · Cited by 4
Self-citation
Metadata
- Authors
- Peng, R., Zhang, R., Lin, G., Yang, X., Li, Z., Zhang, K., Zhang, J., & Li, J.
- Venue
- The Journal of Molecular Diagnostics
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 19
- Issue
- 5
- Pages
- 766-775
- ISSN
- 1525-1578
- Cited by
- 10
- References
- 0
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 833 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CRISPR/Cas9 Technology–Based Xenograft Tumors as Candidate Reference Materials for Multiple EML4-ALK Rearrangements Testing. https://app.cochat.ai/papers/10.1016/j.jmoldx.2017.06.003
- The paper
- Peng, R., Zhang, R., Lin, G., Yang, X., Li, Z., Zhang, K., Zhang, J., & Li, J. (2017). CRISPR/Cas9 Technology–Based Xenograft Tumors as Candidate Reference Materials for Multiple EML4-ALK Rearrangements Testing. The Journal of Molecular Diagnostics. https://doi.org/10.1016/j.jmoldx.2017.06.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.